Revolution Medicines Inc. (NASDAQ: RVMD) Climbs to New 52-Week HighShares of Revolution Medicines, Inc. (
NASDAQ: RVMD) traded at a new 52-week high today and are currently trading at $35.52. So far today, approximately 1.12M shares have been exchanged, as compared to an average 30-day volume of 1.43M shares.
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Capri Holdings Limited (NYSE – CPRI), Avid® (Nasdaq - AVID), EQRx, Inc. (Nasdaq - EQRX)BALA CYNWYD, Penn., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
RVMD Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Revolution Medicines, Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of Revolution Medicines, Inc. (
NASDAQ: RVMD) and EQRx, Inc. is fair to Revolution Medicines shareholders.
Revolution Medicines, Inc. to Acquire EQRx, Inc. in All-Stock Transaction to Gain More Than $1 Billion in Additional CapitalRevolution Medicines Expects to Conduct Late-Stage Development of RAS(ON) Inhibitor Drug Candidate Pipeline Supported by Fortified Balance Sheet
Revolution Medicines Reports Third Quarter 2022 Financial Results and Update on Corporate ProgressDose escalation ongoing in Phase 1/1b trials evaluating two RAS(ON) Inhibitor drug candidates, RMC-6236 (RASMULTI inhibitor) and RMC-6291 (KRASG12C inhibitor)
